---
title: "Dr. Reddy's Laboratories Limited (RDY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RDY.US.md"
symbol: "RDY.US"
name: "Dr. Reddy's Laboratories Limited"
industry: "Pharmaceuticals"
datetime: "2026-05-20T11:33:03.480Z"
locales:
  - [en](https://longbridge.com/en/quote/RDY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RDY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RDY.US.md)
---

# Dr. Reddy's Laboratories Limited (RDY.US)

## Company Overview

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.drreddys.com](https://www.drreddys.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: C (0.42)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 52 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -2.61% |  |
| Net Profit YoY | -28.48% |  |
| P/B Ratio | 2.80 |  |
| Dividend Ratio | 0.53% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 11197567908.50 |  |
| Revenue | 3750249250.05 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 12.06% | B |
| Profit Margin | 12.76% | B |
| Gross Margin | 52.77% | B |
| Revenue YoY | -2.61% | D |
| Net Profit YoY | -28.48% | D |
| Total Assets YoY | 6.55% | B |
| Net Assets YoY | 2.31% | C |
| Cash Flow Margin | 132.45% | B |
| OCF YoY | -2.61% | D |
| Turnover | 0.63 | B |
| Gearing Ratio | 34.33% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Dr. Reddy's Laboratories Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-2.61%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-28.48%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.80",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.53%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "11197567908.50",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3750249250.05",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "12.06%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "12.76%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "52.77%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-2.61%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-28.48%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.55%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.31%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "132.45%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-2.61%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.63",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "34.33%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 23.41 | 40/189 | 18.38 | 17.71 | 17.08 |
| PB | 2.80 | 108/189 | 3.00 | 2.88 | 2.76 |
| PS (TTM) | 2.99 | 77/189 | 3.11 | 2.98 | 2.87 |
| Dividend Yield | 0.53% | 32/189 | 0.54% | 0.52% | 0.50% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 40% |
| Hold | 2 | 40% |
| Sell | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 13.45 |
| Highest Target | 16.45 |
| Lowest Target | 11.04 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RDY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RDY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RDY.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RDY.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**